We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Autoantibodies Combined With Tumor Markers Detect Lung Cancer

By LabMedica International staff writers
Posted on 26 May 2022
Print article
Image: UniCel DxI 800 Access Immunoassay System (Photo courtesy of Beckman Coulter)
Image: UniCel DxI 800 Access Immunoassay System (Photo courtesy of Beckman Coulter)

Lung cancer (LC) is one of the most common cancers in the world and is the primary cause of cancer-related death. According to the pathological type, LC can be categorized into small cell LC (SCLC) and non-small cell LC (NSCLC). NSCLC includes squamous cell carcinoma (LSC), adenocarcinoma (LAC), and large cell cancer.

Gene mutation and recombination occur in cells in the early stage of disease, and related antigens are released. These antigens are recognized by the immune system, which produces antibodies against the antigen as autoantibodies for lung cancer. The autoantibodies can be detected in the blood during the first five years of imaging diagnosis of LC due to the sensitivity and stability of the immune system.

Medical Laboratory Scientist at the Ningbo Medical Center (Ningbo, China) included in a study 780 patients with pulmonary nodules: 633 patients diagnosed with LC and 147 patients with benign lung disease. Among 633 patients with LC, 314 were male with an average age of 60 years (range, 17–83 years), and 319 were female with an average age of 59 years (range, 25–85 years).

ELISA was used to detect the levels of the autoantibodies (TAAbs), and chemiluminescence immunoassay was used to test the levels of the tumor markers. The diagnostic efficacy of the TAAbs combined with the tumor markers for lung cancer was evaluated by receiver operating characteristic (ROC) curves. Seven TAAbs were detected using assay kits (Hangzhou Cancer probe Biotech Company, Hangzhou City. China) and the levels of the TAAbs were measured with Microplate Reader (ST360, Shanghai Kehua Biotechnology Co., Ltd., Shanghai, China; Website). The three tumor markers were detected using Unicel DxI800 (Beckman Coulter, Brea, CA, USA).

The team reported that the positive rate of the combined detection of seven TAAbs and three tumor markers in lung cancer (37.8%) was higher than that in other three groups. The positive rates of SOX2, GAGE7, MAGE A1, CAGE, CYFRA21-1, and SCCA had differences among the four groups. Compared with the benign lung disease group, only GAGE7, CYFRA21-1, and SCCA differed among the groups. The combined sensitivity of the TAAbs was 29.1% (AUC, 0.594), the combined sensitivity of all the markers was 37.8% (AUC, 0.660), and Youden's index was 0.196. In the lung cancer group, CYFRA21-1 had a significant difference in age and sex, and SOX2, MAGE A1, CYFRA21-1, NSE, and SCCA were significantly different in pathological type and tumor–node–metastasis (TNM). In contrast, p53 and GBU4-5 showed no significant differences in age, sex, pathological type, and TNM.

The authors concluded that the combination of these seven TAAbs and three tumor markers could be useful in early diagnosis of LC, and the efficiency of combined detection was better than that of individual detection. The study was published on May 21, 2022 in Journal of Clinical Laboratory Analysis.

Related Links:
Ningbo Medical Center 
Hangzhou Cancer probe Biotech Company 
Shanghai Kehua Biotechnology 
Beckman Coulter

Platinum Supplier
Hormonal Test
Endocrine Array
New
Human Anti-S. Cerevisiae Antibodies Test
ASCA-CHEK
New
TSI Stimulating Assay
Thyretain TSI Stimulating Reporter BioAssay
New
5-Diff Auto Hematology Analyzer
iCell-8800

Print article
IIR Middle East

Channels

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.